Showing results (21-30 of 39) with videos related to
Sort By:
Pageof 4
Journal of Clinical Lipidology|July 26, 2025
Patient experience with familial chylomicronemia syndrome before and after olezarsen treatment: Qualitative interviews with clinical trial participantsAsia Sikora Kessler, T Michelle Brown, Emily Bratlee-Whitaker, et al.Journal of Clinical Lipidology|November 19, 2022
Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study: Volanesorsen in FPLD; The BROADEN StudyElif A Oral, Abhimanyu Garg, Joseph Tami, et al.Journal of Clinical Lipidology|May 12, 2018
Clinical and biochemical features of different molecular etiologies of familial chylomicronemiaRobert A Hegele, Amanda J Berberich, Matthew R Ban, et al.Circulation Research|April 2, 2013
Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humansMark J Graham, Richard G Lee, Thomas A Bell, et al.American Heart Journal|March 10, 2025
Design and rationale of the CORE-TIMI 72a and CORE2-TIMI 72b trials of olezarsen in patients with severe hypertriglyceridemiaNicholas A Marston, Brian A Bergmark, Veronica J Alexander, et al.Journal of Clinical Lipidology|July 28, 2022
Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemiaEwa Karwatowska-Prokopczuk, Jean-Claude Tardif, Daniel Gaudet, et al.The Lancet. Diabetes & Endocrinology|April 2, 2021
Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialIoanna Gouni-Berthold, Veronica J Alexander, Qingqing Yang, et al.The New England Journal of Medicine|September 3, 2020
Antisense Inhibition of Prekallikrein to Control Hereditary AngioedemaDanny M Cohn, Nicholas J Viney, Lauré M Fijen, et al.The New England Journal of Medicine|April 8, 2024
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular RiskBrian A Bergmark, Nicholas A Marston, Thomas A Prohaska, et al.American Heart Journal|March 13, 2025
Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk: Rationale and design of the Essence-TIMI 73b trialBrian A Bergmark, Nicholas A Marston, Thomas A Prohaska, et al.Pageof 4